Woodline Partners LP reduced its stake in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) by 21.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,690,787 shares of the company's stock after selling 739,373 shares during the quarter. Woodline Partners LP owned 2.52% of Annexon worth $13,804,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. TFG Asset Management GP Ltd grew its stake in shares of Annexon by 78.5% during the fourth quarter. TFG Asset Management GP Ltd now owns 1,400,000 shares of the company's stock valued at $7,182,000 after buying an additional 615,645 shares during the last quarter. Shay Capital LLC bought a new position in shares of Annexon during the fourth quarter valued at about $159,000. Sphera Funds Management LTD. bought a new stake in shares of Annexon in the fourth quarter worth about $6,377,000. Rafferty Asset Management LLC grew its stake in shares of Annexon by 23.5% in the fourth quarter. Rafferty Asset Management LLC now owns 218,369 shares of the company's stock worth $1,120,000 after purchasing an additional 41,544 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its stake in shares of Annexon by 5.6% in the fourth quarter. Point72 Asset Management L.P. now owns 5,626,796 shares of the company's stock worth $28,865,000 after purchasing an additional 299,798 shares during the last quarter.
Annexon Price Performance
ANNX traded up $0.05 on Friday, hitting $2.11. The company had a trading volume of 951,998 shares, compared to its average volume of 1,789,807. Annexon, Inc. has a 52-week low of $1.29 and a 52-week high of $7.85. The stock has a fifty day simple moving average of $1.86 and a 200-day simple moving average of $3.47. The firm has a market capitalization of $231.50 million, a P/E ratio of -2.01 and a beta of 1.24.
Annexon (NASDAQ:ANNX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.07). Equities research analysts expect that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
ANNX has been the topic of several recent analyst reports. Needham & Company LLC cut their target price on Annexon from $16.00 to $11.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. HC Wainwright cut their target price on Annexon from $20.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th.
Read Our Latest Report on Annexon
About Annexon
(
Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
See Also
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
